{"id":"W4389328383","doi":"10.1016/j.annonc.2023.11.017","title":"Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen's University","funders":"Janssen Pharmaceuticals; National Cancer Institute; Genentech; Ipsen; European Society for Medical Oncology; Cilag; Sanofi Australia; Astellas Pharma; European School of Oncology; Advanced Accelerator Applications; Daiichi Sankyo Europe; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Sanofi; Exelixis; Prostate Cancer Foundation; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; AstraZeneca; Astellas Pharma US; Takeda Oncology; Amgen; Pfizer","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Clinical endpoint; Internal medicine; Surrogate endpoint; Cancer; Metastasis; Prostate; Survival analysis; Clinical trial; Urology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006094786,0.0005470181,0.0007065766,0.0005309782,0.0003807032,0.001724306,0.0004901612,0.0005120817,0.0008603467],"category_scores_gemma":[0.01093402,0.0001606987,0.0006056412,0.0006265213,0.0004915508,0.0006190821,0.0005992816,0.001389657,0.0003728402],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006862836,"about_ca_system_score_gemma":0.001722402,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001379853,"about_ca_topic_score_gemma":0.002902668,"domain_scores_codex":[0.9970418,0.001725594,0.0001715565,0.0002778197,0.000552939,0.0002303261],"domain_scores_gemma":[0.9927949,0.003300481,0.001744751,0.0006401134,0.0009988609,0.0005209045],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01557537,0.0009040067,0.8458548,0.0005471332,0.0008367719,0.0003216949,0.0005825475,0.005922032,0.02651503,0.0018639,0.00319787,0.09787896],"study_design_scores_gemma":[0.0005414048,0.01987592,0.9038902,0.0002965211,0.001589723,0.002063096,0.0005742574,0.02687962,0.02467658,0.002311514,0.01716372,0.0001374675],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985128,0.004729511,0.004401625,0.000526074,0.0001977091,0.00009307721,0.001180713,0.00005882388,0.003684461],"genre_scores_gemma":[0.9970238,0.0004535817,0.001164877,0.0001439877,0.00008290483,0.00005981488,0.0006380123,0.00001481067,0.0004181261],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006094786,"threshold_uncertainty_score":0.0322327,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1393016692138752,"score_gpt":0.4525994068801056,"score_spread":0.3132977376662304,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}